BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 15985189)

  • 1. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
    Hislop J; Quayyum Z; Elders A; Fraser C; Jenkinson D; Mowatt G; Sharma P; Vale L; Petty R
    Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
    Dretzke J; Round J; Connock M; Tubeuf S; Pennant M; Fry-Smith A; Hulme C; McCabe C; Meads C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):63-70. PubMed ID: 21047493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Huse DM; von Mehren M; Lenhart G; Joensuu H; Blanke C; Feng W; Finkelstein S; Demetri G
    Clin Drug Investig; 2007; 27(2):85-93. PubMed ID: 17217313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States.
    Sanon M; Taylor DC; Parthan A; Coombs J; Paolantonio M; Sasane M
    J Med Econ; 2013; 16(1):150-9. PubMed ID: 22762291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Loveman E; Cooper K; Bryant J; Colquitt JL; Frampton GK; Clegg A
    Health Technol Assess; 2012; 16(23):iii-xiii, 1-137. PubMed ID: 22564553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer.
    Bond M; Hoyle M; Moxham T; Napier M; Anderson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():69-74. PubMed ID: 19804692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose.
    Hislop J; Mowatt G; Sharma P; Fraser C; Elders A; Jenkinson D; Vale L; Petty R
    J Gastrointest Cancer; 2012 Jun; 43(2):168-76. PubMed ID: 21971958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
    Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
    Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
    Dalziel K; Round A; Stein K; Garside R; Price A
    Health Technol Assess; 2004 Jul; 8(28):iii, 1-120. PubMed ID: 15245690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.
    Prenen H; Dumez H; Stefan C; Hoeben A; Wouters C; Van Lierde MA; Sciot R; van Oosterom AT; Peeters M; Polus M; Duck L; Gil T; Schöffski P
    Acta Gastroenterol Belg; 2006; 69(4):367-71. PubMed ID: 17343077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).
    Mabasa VH; Taylor SC; Chu CC; Moravan V; Johnston K; Peacock S; Knowling M
    J Oncol Pharm Pract; 2008 Sep; 14(3):105-12. PubMed ID: 18524863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib: a review of its use in the management of gastrointestinal stromal tumours.
    Siddiqui MA; Scott LJ
    Drugs; 2007; 67(5):805-20. PubMed ID: 17385949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
    Contreras-Hernández I; Mould-Quevedo JF; Silva A; Salinas-Escudero G; Villasís-Keever MA; Granados-García V; Dávila-Loaiza G; Petersen JA; Garduño-Espinosa J
    Br J Cancer; 2008 Jun; 98(11):1762-8. PubMed ID: 18506179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal use of targeted agents for advanced gastrointestinal stromal tumours.
    Reichardt P
    Oncology; 2010; 78(2):130-40. PubMed ID: 20389135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.